What's Happening?
Ionis Pharmaceuticals has completed enrollment for the pivotal cohort of its Phase 3 REVEAL study, which evaluates obudanersen, an investigational RNA-targeted medicine for Angelman syndrome (AS). The study involves 136 participants aged 2 to under 18
years with confirmed AS. The adult cohort is expected to complete enrollment by the third quarter of 2026. Obudanersen aims to treat AS by increasing the production of UBE3A protein. The U.S. FDA and European Medicines Agency have granted Orphan Drug designation to obudanersen, with additional Fast Track and Rare Pediatric designations from the FDA.
Why It's Important?
The completion of this pivotal cohort marks a significant step towards potentially providing a disease-modifying treatment for Angelman syndrome, a rare neurodevelopmental disorder with no approved therapies. The study's outcomes could lead to a breakthrough in managing AS, improving the quality of life for affected individuals and their families. Successful results could also bolster Ionis Pharmaceuticals' position in the field of RNA-targeted therapies, potentially influencing future research and development in similar genetic disorders.
What's Next?
Topline data from the REVEAL study is anticipated in the second half of 2027. Ionis plans to advance obudanersen into the Phase 3 CHAMPION study, targeting different genetic profiles of AS. The CHAMPION study is expected to begin before the end of 2026. These developments will be closely monitored by the medical community and stakeholders in the pharmaceutical industry, as they could pave the way for new treatment paradigms in genetic and neurodevelopmental disorders.
